Olaparib: Why HRD in breast and ovarian cancer goes beyond BRCA
Olaparib demonstrated activity in HR-deficient metastatic triple-negative breast cancer and platinum-sensitive relapsed ovarian cancer without germline BRCA1/2 mutations.
Lung cancer in never smokers: The 60x risk factor you might be missing
A specific EGFR variant significantly increases lung cancer risk in individuals who have never smoked, challenging traditional views on lung cancer etiology. This genetic predisposition highlights a critical, often overlooked, pathway to disease development.
Multicancer early detection: Can we screen for what we can't treat?
An FDA advisory panel has supported the clinical utility of multicancer early detection (MCED) tests, marking a potential shift in cancer screening paradigms.
Chemo hair loss: Why some patients feel it more deeply
Breast cancer home injections: Convenient for patients, complex for insurers
Salivary gland cancer: Is HER2-low the new HER2-positive?
Why are we still treating cancer prevention as adjunctive care?
Brain metastases: Why less radiation, more often, improves outcomes
ACLF: Why G-CSF works for some, but fails others
Specific immune cell populations and inflammatory markers predict G-CSF treatment response and mortality in acute-on-chronic liver failure, a GRAFT sub-study shows.
MASH: Why diabetes management now demands a liver-first approach?
Emerging liver-directed approaches for moderate to advanced MASH are reshaping treatment paradigms, with significant implications for diabetes specialists managing metabolic dysfunction.
Bepirovirsen: Can a new antisense approach achieve functional cure in chronic hepatitis B?
Bepirovirsen, an antisense oligonucleotide, aims to reduce hepatitis B surface antigen (HBsAg) levels, a key step towards functional cure in chronic hepatitis B. The therapy targets viral RNA, disrupting protein production and potentially allowing immune restoration.
Chronic hepatitis B: Is PD-1 blockade the key to T-cell revival?
Why primary sclerosing cholangitis remains a therapeutic graveyard
Cholangiocarcinoma Surveillance: What Interval, What Modality in PSC?
Liver disease: Is coffee a daily dose of prevention?
Seladelpar and elafibranor: second-line options for PBC
Hypertension: Do shorter wall squats work as well for older women?
Isometric wall squats reduced blood pressure in older women with hypertension, but a higher dose did not offer superior postexercise hypotension.
LAA occlusion: Less bleeding, but is stroke risk truly equal?
Left atrial appendage occlusion (LAAO) reduces nonprocedural bleeding in AF patients but shows no difference in stroke or mortality compared to medical therapy.
Beyond diagnosis: ECG waveforms predict MI-E treatment response
Electrocardiogram waveforms offer insights into myocardial infarction with epicardial coronary artery disease (MI-E) efficacy, providing a non-invasive window into myocardial health.
Endocarditis: Why fixed-dose ampicillin often misses the mark
Rethinking xylitol: Is this 'healthy' sugar substitute a cardiac threat?
Peripheral arterial disease: Why early detection still eludes us
Evolocumab: Is LDL-C reduction finally translating to lives saved?
Tactical athletes need more than a sports physical
Rotavirus vaccine and T1D: Is an 11% rise cause for alarm?
Type 1 diabetes incidence in Norwegian children rose 11% after rotavirus vaccination began, but similar rises followed unrelated vaccine changes.
Low-carb diets in kids with type 1 diabetes: safe, but not standard?
In 45,569 children, very low carbohydrate diets were not linked to poorer growth, severe hypoglycaemia or ketoacidosis, though the evidence remains observational.
Survodutide: Is 9.8% weight loss enough for its GI cost?
SYNCHRONIZE-2 in NEJM: survodutide 6.0 mg cut weight 9.8% versus 3.9% on placebo over 76 weeks in type 2 diabetes, but about 1 in 4 stopped treatment.
CBL-514: Is visceral fat reduction the real story?
The 2026 ADA/EASD consensus: Why early SGLT2/GLP-1 works
Type 1 diabetes screening: Why one protocol worked across 8 nations
Bariatric surgery: The hidden hernia risk you're missing
Amylin plus tirzepatide: Is 23% weight loss the new benchmark?
Brexpiprazole for Alzheimer's agitation: Antidepressants don't change efficacy
A post hoc analysis found brexpiprazole reduced agitation in Alzheimer's dementia, with similar efficacy regardless of concomitant antidepressant use.
Tau: Why its 'knockout' effect is a clue to Alzheimer's
Tau hyperphosphorylation impairs cooperative binding to microtubules and disrupts lysosome trafficking in neurons, mimicking tau knockout effects.
Epilepsy: Is art the missing piece in holistic patient care?
A new exhibit showcases artists living with epilepsy, aiming to reframe public perception of the condition beyond its clinical manifestations.
Can mice learn to control their own brains? A new neurofeedback system
Lifelong odor sensitivity: What early exposure means for your patients?
Routine childhood vaccines: Less coverage means more than just infections
Parkinson's cognitive decline: Is Juvmo the answer we overlooked?
Fibromyalgia: Is the pain real if the tissue damage isn't?
LeukemiaAplastic Anaemia: Why clonal evolution is not just a complication, but a roadmap
Get the full storyRusfertide and hepcidin mimetics: a different way to control erythrocytosis
Get the full storyHaematocrit targets: Is 45% still the right threshold for phlebotomy?
Get the full storyWhy molecular response in polycythemia vera remains an elusive endpoint
Get the full storyPNH: Beyond Eculizumab, How Proximal Inhibition Reshaped Treatment Goals
Get the full storyWhen complement inhibitors fail: Recognizing breakthrough haemolysis
Get the full storyOral factor B inhibition: a new path for PNH management?
Get the full storyMyelofibrosis: Why transplant timing dictates survival, not just symptoms
Get the full storyChoosing a JAK Inhibitor in Myelofibrosis: Beyond Ruxolitinib
Get the full storyMomelotinib and anaemia in myelofibrosis: a new calculus for treatment?
Get the full story
Arthritis RheumatoidSjögren's Disease: Bridging the 5-Year Diagnostic Gap to Emerging Therapies
Get the full storySjögren's Disease: New Therapies Target Underlying Immune Pathways
Get the full storySjögren's Disease: Early Damage Often Present at Diagnosis
Get the full storyCrystal Arthritis: The ICU Fever You Keep Missing
Get the full storyWhen Joint Pain Strikes: Distinguishing Gout, Pseudogout, and Septic Arthritis
Get the full storyCalcium Pyrophosphate Deposition Disease: What the 2023 Criteria Enable
Get the full storyAntiphospholipid Antibody Testing: When to Trust the Results
Get the full storyWhy triple-positive antiphospholipid syndrome defies direct oral anticoagulants
Get the full storyStatin-associated myopathy: rare, real, and reversible?
Get the full storyMyositis-Specific Autoantibodies: Predicting Prognosis and Guiding Screening
Get the full story
Idiopathic Pulmonary FibrosisIPF: Why new therapies are still missing the mark
Get the full storyAlpha-1 Antitrypsin Deficiency: Why fragmented care costs lives
Get the full storyRespiratory care: Why neurology's long-acting therapies could be key
Get the full storyRethink PDE inhibition in COPD: Not all isoforms are equal
Get the full storySevere asthma: Why targeted therapies miss some Type 2 patients
Get the full storyPH-ILD: Why current vasodilators fall short, and what's next
Get the full storyBeyond rescue inhalers: What really keeps COPD patients out of hospital?
Get the full storyCOPD exercise limits: Is your oxygen therapy doing enough?
Get the full storyChronic lung disease: Why early diagnosis still isn't enough
Get the full storySleep Apnea: Why AHI Misses What Matters Most
Get the full story
Clostridioides difficileNatural spring water: Why 'pure' can still mean peril for patients
Get the full storyFoodborne outbreaks: Are we seeing more, or just reporting better?
Get the full storyRSV and COVID-19 vaccines: Why are we still underestimating their impact?
Get the full storyBixlenvo: Is the smallest HIV pill also the biggest advantage?
Get the full storyDolutegravir for HIV in newborns: A new option for an urgent need
Get the full storyUndiagnosed TB deaths in England highlight diagnostic failures
Get the full storySerology and PCR: Optimising COVID-19 Episode Identification
Get the full storyCongenital Syphilis: The Missed Testing Opportunities Behind Rising Case Counts
Get the full storyAsymptomatic bacteriuria: The treatment decision that fuels antibiotic resistance
Get the full storyWhy syphilis rates keep climbing in high-income countries
Get the full story
Acne VulgarisEpithelial health: more than a symptom of chronic inflammation?
Get the full storyDermatomyositis: Why an oral JAK inhibitor changes everything
Get the full storyCould immune system modulation be the next frontier in skincare?
Get the full storyWhy hidradenitis suppurativa takes seven years to diagnose
Get the full storyWhy rosacea flushing resists standard therapy: a neurovascular disconnect
Get the full storyMatching rosacea therapy to dominant features: A phenotype-led approach
Get the full storyDoes targeting Demodex mites improve rosacea outcomes?
Get the full storyAntihistamine-refractory urticaria: when standard care falls short
Get the full storyChronic Urticaria: The Diagnostic Tests That Rarely Help
Get the full storyRemibrutinib: A New BTK Inhibitor for Chronic Urticaria Beyond Omalizumab
Get the full storyLate-stage oral PCSK9 inhibitors could expand reach tenfold, changing clinical and commercial math.
A scientific first is approved for sickle cell disease; understanding the path to scale is now critical.
R-CHOP has been standard of care for 20 years. frontMIND may be the beginning of the end
An epidemiological shift in T2D is reshaping drug development and market access for oncology and metabolic portfolios.
The most resistant cancer is finally responding, and the pipeline is accelerating
OrlandoNov 6 – 11 2026Get on-site reporting the moment it publishes.
OrlandoAttending ACR 2026?
Get our free prep guide: key sessions by day, satellite symposia listings, and recommended spots near the venue.
Free. No spam. Unsubscribe anytime.
